Exosomes are cell derived nanoparticles that can dial down inflammation. Two treatments, several days apart helped a single patient avoid a facial skin graft, but proving it works for others will take a controlled trial.
Kaitlin Jeffrey, an 18-year-old Western University student from Toronto, was three months into her first year when a December 2025 house fire in London, Ontario left her with severe facial burns. Her surgeons at Hamilton Health Sciences told her a facial skin graft was likely. Her family began to prepare for years of reconstructive work.
Then her burn team tried something else.
On compassionate grounds, with no approved option for the kind of deep facial injury she had, surgeons injected two treatments of exosomes into Kaitlin's burns, several days apart. Exosomes are tiny particles that cells use to talk to each other. In wound care, they can dial down inflammation and signal skin cells to repair faster. The ones Kaitlin received were collected from cells grown in a lab and delivered straight into the damaged tissue.
Within weeks, the team said, the burns began to close without surgery. Kaitlin did not need a graft on her face. Dr. Marc Jeschke, the burn surgeon who performed the procedure, said the outcome was better than what a skin graft would have achieved. "You can do the best graft on the planet, but you won't return the skin to normal," he said. Hamilton Health Sciences, in a June 15 release on PR Newswire, described it as the world's first use of exosome therapy to treat human burns.
The case is real, and the result is meaningful for the patient in front of the team. It is also one patient.
Exosomes have been studied in burn research for years in animal and lab models, and they have been tested in human trials for other wound types, including diabetic ulcers. What has been missing is a published clinical trial in burns. Hamilton Health Sciences says Kaitlin's case is the first reported human use in this indication. The release also pointed to another young patient from the same fire, treated with standard skin grafting, and said the exosome patient "healed faster, and with better results." That is a paired anecdote, not a controlled comparison. A burn surgeon who did not see the cases would not be able to draw a clean line between the two recoveries without knowing how deep the burns were, where they sat on the body, and what other care each patient received.
A few things are worth holding in mind before this gets read as a new standard of care.
Compassionate grounds is a Health Canada pathway that lets a clinician offer an unapproved treatment to a single patient who has run out of approved options. It is not a green light, and it is not a clinical trial. The bar is the patient in front of the team, not the population that might come next.
Hospital press releases, including this one, are written to claim credit. "World-first" and "honestly a miracle" (Kaitlin's own description) are language that sits in the same release that omits a peer-reviewed dataset, a dosing protocol, and independent corroboration. A single compassionate-use case with a good outcome is a research opening. It is the kind of opening that should lead to a small, controlled trial, with a defined product, defined doses, and a way to compare treated patients against a fair benchmark.
Independent burn researchers, exosome scientists, and bioethicists will want to see that trial. Until then, the honest read of the Hamilton case is narrower than the headline: one teenager, two treatments several days apart, one outcome that matches what years of preclinical work had suggested might be possible. The next patient should not have to rely on a press release. The next patient should get the answer to a clinical question that has been waiting to be asked.